Registration is open for the 2024 ASRM Scientific Congress & Expo

Close Close Icon
Ethics Committee teaser

Planned oocyte cryopreservation to preserve future reproductive potential: an Ethics Committee opinion (2023)

Planned oocyte cryopreservation is an ethically permissible procedure that may help individuals avoid future infertility. Because planned oocyte cryopreservation is new and evolving, it is essential that those considering using it be informed about the uncertainties regarding its efficacy and long-term effects. This replaces the document of the same name, last published in 2017. (Fertil Steril® 2024;121:604-12. ©2023 by American Society for Reproductive Medicine.)



  • For individuals attempting to extend their reproductive window in the face of expected reproductive aging, and for transgender men who will experience the loss of female gametes in the process of transitioning from female to male, advanced oocyte cryopreservation (‘‘OC’’) is ethically permissible. The Ethics Committee will refer to this procedure as ‘‘planned oocyte cryopreservation’’ or ‘‘planned OC.’’ Planned OC serves legitimate interests in reproductive autonomy.
  • Planned OC is relatively new, and uncertainties exist regarding its efficacy, appropriate use, and long-term effects.
  • Providers should ensure that individuals who request planned OC are informed about its efficacy, safety, costs, benefits, and risks, including the unknown long-term health effects for offspring. Because of the uncertainties that accompany this developing procedure, there are distinct obligations regarding disclosure and informed decision-making. Providers should disclose their own clinic-specific statistics, or lack thereof, for successful freeze-thaw and live birth. Patients should be informed that medical benefits are uncertain and harms that are not fully understood may emerge from planned OC.
  • To improve scientific understanding of planned OC, including efficacy, advisability, and long-term effects, medical professionals offering this procedure are encouraged to collect outcome data, conduct research, and report planned OC cycles to the Society for Assisted Reproductive Technology.

The ability to cryopreserve gametes and embryos has created important reproductive options. It has given individuals facing the potential loss of reproductive capacity, such as those receiving gonadotoxic medical treatment, the chance to have biologically related children in the future. The history of cryopreservation of sperm, embryos, and oocytes is set forth in the American Society for Reproductive Medicine (ASRM) Practice Committee document, ‘‘Evidence-based outcomes after oocyte cryopreservation for donor oocyte in vitro fertilization and planned oocyte cryopreservation: a guideline’’ (1). Although the first human birth from a previously frozen oocyte occurred in 1986, laboratory techniques such as vitrification and intracytoplasmic sperm injection have led to a marked improvement in the efficacy of oocyte cryopreservation (OC) (2).

Oocyte cryopreservation was classified initially by ASRM as experimental. In 2012, the ASRM Practice Committee removed the experimental label after a thorough review of the scientific literature. The report concluded that in vitro fertilization (IVF) and pregnancy rates with cryopreserved oocytes compared favorably to those with fresh oocytes. In addition, short-term studies of the health of offspring from OC revealed no increases in congenital anomalies compared with other IVF offspring (2). Although the ASRM Practice Committee and Ethics Committee approved the use of OC for patients facing therapies likely to be gonadotoxic (2– 4), the Practice Committee declined at that time to recommend OC ‘‘for the sole purpose of circumventing reproductive aging in healthy women’’ on the grounds that there were insufficient data on the ‘‘safety, efficacy, ethics, emotional risks, and cost-effectiveness’’ for that indication (2).

Since that time, further research on efficacy has been reassuring (5, 6). Increasing numbers of women are seeking planned OC, and increasing numbers of physicians are providing it (7–13). Additionally, planned OC expands reproductive options for transgender men, who will experience the loss of female gametes in the process of transitioning from female to male. In 2014, ASRM published a fact sheet on its patient education website, describing how individuals may use OC even when they are not facing a fertility-threatening disease (14). All these factors point to planned OC as a medical innovation that is moving into practice, raising ‘‘ethical issues involving evaluation of evidence, balancing benefits and harms, supporting patient autonomy, avoiding conflict of interest, and promoting advances in health care’’ (15). This Committee Opinion addresses the ethical issues that arise when OC is used by individuals whose goal is to protect their ability to have children in the future, apart from an immediate threat from gonadotoxic therapy.

Although the ovarian stimulation and oocyte retrieval required for OC are medical procedures that are well-tested, used worldwide, and regarded as safe, caution is warranted. There is a risk of misplaced confidence in the effectiveness of this procedure, as well as scientific unknowns concerning long-term and transgenerational offspring health. Mindful of these cautions, however, this Committee finds the use of OC for those attempting to extend their reproductive potential for the future to be ethically permissible after informed consent.

The Ethics Committee previously supported OC for individuals facing immediate, medically induced loss of fertility (4). But there are many less-immediate developments that could also threaten a person’s ability to have children in the future. These developments include diseases, ovarian insufficiency, traumatic injury, the planned female-to-male gender transition, and the fertility loss that occurs with reproductive aging. Planned OC may also benefit those seeking children in response to unanticipated future events such as remarriage or the death of an existing child (16).

After the 2022 Supreme Court’s reversal of Roe v. Wade, there is no longer a federally protected constitutional right to abortion at any stage of pregnancy, and states may regulate abortion under a ‘‘rational basis’’ standard rather than the previous ‘‘strict scrutiny’’ standard (17). The impacts on reproductive choice and autonomy for patients, providers, and third-party participants in assisted reproductive technology therapy are still unfolding and may vary depending on state laws that extend or restrict access to abortion and reproductive care. To the extent a restrictive, applicable state law may explicitly or implicitly apply to IVF preimplantation embryos, additional considerations as to where to create or store IVF embryos and cryopreserving gametes rather than embryos should be considered. This may increase demand for OC.


The appropriate language to describe the process of preserving oocytes for future fertility is unsettled. ‘‘Oocyte cryopreservation’’ or ‘‘OC’’ is the most generic terminology and does not distinguish the rationale for oocyte preservation. When OC is used in contexts other than to avoid immediate gonadotoxic effects, observers have criticized terms like ‘‘social egg freezing,’’ ‘‘freezing for nonmedical reasons,’’ and ‘‘elective’’ OC. Such terms may trivialize the fact that the treatment is being undertaken to avert infertility that, when it arises, will in fact be a medical condition (18, 19). The Ethics Committee concurs. Researchers in the United Kingdom have suggested the term ‘‘oocyte cryopreservation for Anticipated Gamete Exhaustion’’ or ‘‘AGE’’ (18). The Committee believes a more general term is merited, however, because the circumstances that lead to the use of the oocytes may be other than advancing age. The critical difference between the OC examined in this opinion and that which is done when gonadotoxic therapy is imminent is its nonemergent nature. It is being undertaken as a matter of planning before a medical indication has materialized and will be referred to as ‘‘planned oocyte cryopreservation’’ or ‘‘planned OC.’’ The Ethics Committee recognizes that when many individuals who plan to cryopreserve oocytes identify as female or women, not all do. The committee aims to use gender-neutral language wherever possible.


For decades, women in the United States have been having children at older ages. Nationwide, the rate of first births to women ages 35–39 years has been rising since the 1970s, although it has recently plateaued; the rate of first births to women ages 40–44 years has been rising since the early 1980s (20, 21). Many factors contribute to this trend, but it is well-recognized that increased access to education and participation in the workplace is central. The critical periods of advancement in these pursuits usually take place when individuals are in their 20s and 30s, corresponding with the time at which ovarian reserve begins to decline (22).

This trend is sometimes described as ‘‘delaying’’ or ‘‘postponing’’ childbearing, statements that suggest affirmative choice or even blame that individuals have brought the difficulty on themselves (23). Rather, the data show that many people who want to have children face conflicts about their preferred life path in a culture where the optimal time for educational and career advancement coincides directly with the period that the body is best suited for reproduction. One study cited the lack of a partner as the most common reason individuals elect to undergo planned OC (24). Many individuals report that their life circumstances (partnership, marriage, and finances) are not as they desire them, or as society supports or regards as acceptable, and these circumstances are what prevented them from starting a family at an earlier time (25–29). finally, what may appear to be affirmative delay may actually be the unwitting product of a ‘‘knowledge gap’’: the widespread and persistent overestimation of both reproductive potential at a given age and the ability of reproductive medicine to restore that potential (30).

Given these societal and personal reasons for procreation later in life, a biological truth comes into play: older females increase the risk of infertility because of reduced oocyte quantity and quality, increased chromosomal abnormalities, and increased rates of pregnancy loss. Fertility and offspring health are affected by men's age, too, although not until men are older, generally past age 40 or 50 years. For both sexes, the more time that passes before they reproduce, the greater the chance that some illness, life circumstance, or accident may impair their fertility or reproductive outcomes.

When individuals seek children at a time when their own oocyte quality is compromised, whether because of age, disease, or another cause, they traditionally have had the option to undergo IVF treatment with donor oocytes. Planned OC provides an additional option in this circumstance: when they have previously banked their own oocytes, they may be able to use them for family building. Compared with using donor oocytes, planned OC offers benefits that include maintaining a genetic connection to the offspring, the potentially reduced cost of planned OC compared with multiple cycles of IVF or the use of donor oocytes (23), and avoiding the complexities of working with a reproductive third party. Although planned OC ultimately will be ineffective in some percentage of cases (the value of which is dependent on patient age at the time of cryopreservation and the number of oocytes frozen), it will allow some individuals and couples who otherwise would have had to forego biological parenthood the chance to have genetically related children.

Data on the long-term safety and efficacy of planned OC are incomplete because most oocytes cryopreserved for autologous use have yet to be thawed and utilized. Fortunately, several recent studies have reported outcome data and led to an increased understanding of determinants that predict success, including age at cryopreservation and ovarian reserve (21, 25, 26, 28, 31). Embryos from previously vitrified oocytes show rates of fertilization, implantation, and clinical pregnancy that are comparable to those for embryos from fresh oocytes, although there can be considerable variation among clinics (31–35). Although only short-term, birth reports indicate no increase in congenital abnormalities in infants from cryopreserved oocytes compared with other IVF infants (33, 36, 37). Observational studies of offspring conceived after OC, although limited, show no increased risks compared with the use of fresh oocytes (38). Medical professionals offering planned OC and IVF treatment are strongly encouraged to undertake long-term outcome studies of maternal and fetal health. The Society for Assisted Reproductive Technology will contribute to a greater understanding of success rates as planned OC cycle data from fertility clinics is currently being collected.


A range of viewpoints on planned OC has been presented by researchers and commentators (11, 21, 24–29). Although several commentators raise questions and concerns about planned OC, most conclude it should be available to those who are fully informed and wish to use it (26, 28). The European Society of Human Reproduction and Embryology approved the use of planned OC for fertility preservation in 2012 (30). This section examines the arguments in favor of the planned OC.

The leading argument for planned OC is that it may increase reproductive options, thus enhancing reproductive autonomy. This argument proceeds on several levels. first, planned OC may improve one's ability to organize their education, work, and family building with less pressure from their ‘‘biological clock.’’ A planned OC may allow one time to establish suitable relationships or life circumstances to prepare for having and raising children. It reduces the pressure to have a child when not yet psychologically, socially, or situationally ready (19, 39, 40).

Planned OC further enhances autonomy by potentially eliminating the need for third parties, such as oocyte donors, with the associated complexities and costs. Planned OC also avoids problems from ‘‘second parties;’’ that is, it can allow individuals to control their preserved gametes without the risk that a partner may retract consent to future use, as can happen with frozen embryos. The disputes over embryos that may erupt when gamete providers separate or divorce can pose clinical, emotional, and legal difficulties, all of which are avoidable when individual gametes, rather than embryos, are preserved for later use. Planned OC also provides an option for those who prefer not to form and then cryopreserve embryos (29).

This Committee finds that planned OC is compatible with beneficence, the ethical precept obligating physicians to act for the patient's welfare. As described above, planned OC represents a preventive strategy that may enhance reproductive potential and the health of offspring. Although cryopreserving oocytes in this context is not undertaken in response to an immediate disease, it is undertaken with the goal of preventing infertility in the future. It is worth observing that there is little when any, criticism of those choosing to cryopreserve sperm to protect their future fertility (11). Although the costs, physical demands, and risks of sperm vs. oocyte preservation are certainly different, the benefit considerations are comparable.

Planned OC may also promote social justice by reducing the obstacles women currently face because their reproductive window is narrower than men's. By extending the time when women may start a family, planned OC can lessen the effects of educational and workplace constraints that disparately burden one sex; thus, oocyte cryopreservation can contribute to equality for men and women (11, 21, 30).


This section examines the arguments that raise caution against planned OC. Certain objections revolve around the procedure: a nonmaleficence argument that the intervention is too physically invasive and risky to perform when there is no immediate threat of infertility (41) and that studies have not yet established whether there is a ‘‘shelf life’’ for cryopreserved oocytes or the long-term safety for offspring.

The physical demands of planned OC fall safely within the acceptable bounds of reproductive medicine. It is no more invasive than oocyte donation, which is supported by the ASRM as a matter of reproductive choice and which provides no personal health or reproductive benefits to the donor (ASRM financial Compensation of Oocyte Donors). Planned OC is apt to carry less physical risk than OC before gonadotoxic therapy because the patient is not already afflicted with a serious disease or possibly postponing its treatment (21). The most common risk, that of ovarian hyperstimulation syndrome, is reduced (although not absent) in planned OC because there is no embryo transfer at the end of the stimulation cycle. In addition, gonadotropin-releasing hormone agonist triggers, used in the context of gonadotropin-releasing hormone antagonist cycles, can further decrease the chance of the development of ovarian hyperstimulation (42). 

Another set of objections is rooted in the fact that many oocytes ultimately remain unused, such that both the procedure and its expense may prove to have been unnecessary; individuals may not seek to preserve their oocytes until they are at an age when the oocytes are already compromised (29), and planned OC may provide a false sense of security about an individual’s ability to have children in the future (43). These concerns are synergistic: the younger the age at which individuals bank their oocytes, the less likely they will be utilized given that there is more time for their life plan to unfold (28). Such differences are inherent when prophylactic medical treatments are undertaken, however, and are not unique to planned OC. Similar considerations arise in the decision to cryopreserve oocytes before gonadotoxic therapy; that is, the patient’s need for the oocytes is not certain, the timing of retrieval may be late relative to their age and health, and there may be a risk of false security. Researchers are investigating the question of the optimal window, both biologically and financially, in which to undergo planned OC, and recommendations to guide patients on the advisability of planned OC will continue to emerge (23, 44). In the end, however, the choice to use planned OC and to incur uncertain risks for the prospect of uncertain benefits can be made only by individuals for themselves.

The issue of false security is highlighted when planned OC is referred to as an ‘‘insurance policy’’ for future childbearing, raising a concern that it will lead to an overly confidant reliance on the preserved oocytes. This concern presupposes without basis that the women have other available options, such as immediate marriage or reproduction, that they will dismiss because of the cryopreserved oocytes (17). To the extent that the risk is based on a misunderstanding of the likely success rates of planned OC, it is best addressed through education and informed consent. Physicians and those acting in concert with them should avoid overstatements that may invite or allow misplaced confidence. More broadly, however, in medical contexts, it is not uncommon for patients to grapple with choices about medical options where overreliance is a risk. Patients should be trusted to comprehend information when full and appropriate medical counseling is presented and should not have options removed because of a potentially biased underestimation of their capabilities (45).

Research on this topic may also make a difference. There are ongoing studies on the quality and number of oocytes, by age and hormone levels, needed to have a particular chance of pregnancy when those oocytes are used (23, 32, 44, 46). This information should be communicated to patients. Learning that at age 38 years, approximately 25–30 cryopreserved oocytes are required to have a reasonable chance of having one child helps mitigate the risk of overreliance (5, 46, 47). This research does raise a further issue: planned OC is expensive (23), is usually self-pay (even for OC for many cancer patients at this time), and will often require multiple cycles to attain a reasonable chance of having a child in the future. These factors mean there will be economic and probably racial and ethnic disparities in access to planned OC (25, 47, 48). Few employers offer planned OC as a health benefit, although the trend, at least among some very large employers, appears to be on the rise (49). As it stands, however, only a small subset of those who are interested in using planned OC will find it affordable; the inequitable result is that the educational, career, and life-planning benefits will accrue only to a few. That being said, there are some who contend that corporate coverage of planned OC may confine reproductive autonomy in that it encourages delay of childbearing (49).

Concerns about planned OCs on societal grounds are sometimes voiced. Here one finds the objections that planned OC may promote delayed childbearing, that older parenthood is not fair to children, and that planned OC lets workplaces and the broader society ‘‘off the hook’’ from having to alter policies and demands that constrain individuals’ choices and hinder their success (33, 50), and that planned OC invites a risk of commercial exploitation. Later childbearing is already happening for reasons described previously. When people exercise this aspect of reproductive autonomy, planned OC offers a chance to mitigate the potentially devastating costs of infertility, childlessness, the inability to have the desired number of children, and the increased risks of adverse pregnancy outcomes. Expressions of concern about older parenthood may be tinged with sexism when one considers that parenthood by older men rarely draws the same criticism (11). Moreover, the Committee addressed an analogous issue in its opinion on OC before gonadotoxic therapy and concluded that the risk that offspring will be born to a person with a potentially shortened lifespan is not a reason to deny him or her reproductive treatment (3).

This is not to say that individuals should have pregnancies at any age. Studies indicate that the risks of maternal and neonatal harm increase with the increasing age of the woman carrying the pregnancy (51). This, again, is important information that needs to be conveyed when considering OC (52).

It would be beneficial when workplace and societal norms evolved to achieve equality for women and obviated the draw of so-called ‘‘medicalization,’’ that is, the ‘‘tendency to seek medical answers to social problems’’ (30). However, it does not follow that planned OC, as an available preventive procedure, should be withheld until these ideals are realized. Rather, it is fair to proceed on both fronts concomitantly.

This Committee supports insurance coverage for fertility treatments that expand reproductive choice, including planned OC. The US Department of Defense moved in a positive direction in 2016 when it proposed a temporary pilot program to pay for the preservation of sperm and oocytes for active-duty service members (53). Disappointingly, the program never materialized because it was contained in a budget that ultimately did not become law (54). The Ethics Committee encourages employers and lawmakers to enact policies that reduce the burden of childbearing and child-raising and that promote equality for all in the workplace and around the world. It is important, however, that women are not subjected to pressure to cryopreserve their oocytes and delay childbearing as a demonstration that they are committed to their careers (29).

Commentators have identified the risk of commercial exploitation when planned OC is offered by employers or marketed by those who profit from it (29, 49, 55). The Ethics Committee is concerned about coercion and the line between education and inappropriately aggressive marketing. Messaging in the media or through in-person gatherings may have the benefit of educating women about the decline in future reproductive potential, although they are still good candidates for unassisted reproduction or planned OC, but it may also generate disproportionate fear or encourage action that is not in their best interest (18, 26). In that regard, this Committee disapproves of arrangements in which medical practices hire firms to hold marketing sessions and then pay those firms for each person who becomes a patient. Such arrangements may also raise legal and ethical concerns; practices considering them should obtain legal advice on the laws and issues that are implicated.


Providers should ensure that all who request planned OC are informed about efficacy, safety, benefits, and risks, including the unknown long-term health effects for offspring. Because planned OC is a developing procedure, disclosure and informed decision-making should be consistent with the Ethics Committee Opinion, ‘‘Moving innovation to practice: a committee opinion,’’ which emphasizes the importance of shared decision-making to help patients assess the value the treatment may or may not have for them (10).

first, physicians and those advising potential patients about planned OC should convey that the most assured and lowest-cost way to have a family is to try to conceive through sexual intercourse or donor insemination at a relatively early age (before the mid-30s, keeping in mind the time required to have subsequent children, when desired). Conversations about planned OC should identify all of the options for forming a family: early unassisted reproduction, assisted reproduction with their own oocytes, oocyte donation, embryo donation, adoption, or living childfree. These options should be reviewed again, as appropriate, when patients return to use their cryopreserved oocytes. At the same time, clinicians must be mindful not to interpose their own judgments about an individual's priorities and life plans (17). Some patients presenting for planned OC may do so as a means to deliberately ‘‘buy time’’ to reach a career goal, for example. That prerogative is a matter of personal autonomy; it is not for a physician to substitute his or her differing values.

Those advising patients about planned OC need to be clear about what is and is not yet known. Factors such as the suitable range of ages for planned OC and the number of oocytes needed are still being determined and may vary widely according to clinic experience. Patients may wish to consult with an independent mental health professional before choosing a planned OC to further explore their expectations, motivations, and any concerns surrounding the procedure. In an initial study of 201 women, almost half (49%) subsequently experienced some regret about their decision to cryopreserve oocytes. Factors that increased regret included having fewer oocytes to freeze than anticipated and receiving inadequate information or emotional support (56).

In communicating with potential patients about planned OC success rates, centers need to be specific about the extent of their experience with planned OC and their own results. At a minimum, they should disclose the survival of oocytes after thawing as well as their own pregnancy and live birth rates as they become available. National statistics can supplement this information, but studies indicate it takes experience to become skilled at oocyte vitrification and thawing, and patients deserve to understand their provider's degree of experience (35). In that regard, the prior statement of this committee applies:

  • A patient should be informed when the intervention has been adopted recently by the practice. The provider should share evidence relevant to the expectation that the new intervention is likely to be successful for the patient and how the risks may differ from those of standard treatment. It is important to point out to the patient that published success rates may not be achieved in a setting where a treatment or procedure has been adopted recently. The personal experience of providers with the new techniques or procedures should be discussed, whether the patient asks or not, and potential conflicts of interest should be disclosed (10).
  • Potential patients should be informed, for example, when no patients have yet returned for thawing, fertilization, and transfer, such that the facility's live birth results after OC are not yet established. Some facilities, such as those that provide only egg banking, are not required to report to the Society for Assisted Reproductive Technology or the Centers for Disease Control and Prevention the outcomes of cycles using oocytes they cryopreserved. This lack of reported data also should be disclosed and explained to prospective patients.
  • Consent forms for planned OC should contain information on the process for oocyte cryopreservation, including potential and uncertain risks along with limited safety and outcome data. Patients should be cautioned that this is an emerging technology and that they may not receive any medical benefit from going through the procedure and may incur harm.
  • Consent forms should also address the future disposition of cryopreserved oocytes. Patients should indicate their disposition preferences in the event of death and any wishes regarding posthumous reproduction and inheritance rights (43). The facilities that store oocytes should communicate to patients their policies regarding the consequences of any loss, destruction, or theft of a patient's gametes or nonpayment of storage fees. It is acceptable for consent forms to offer the option of donating unused oocytes for research and for facilities to provide it as a possible disposition when oocytes are unclaimed. In such cases, explicit consent is required, and consent forms should follow the recommendations in the Ethics Committee opinion, ‘‘Informed consent and the use of gametes and embryos for research’’ (57).
  • Consent forms should also include any clinic policies regarding the upper age limit for the future use of cryopreserved oocytes for the purpose of reproduction.


Because the use of planned OC increases, researchers are encouraged to continue to investigate factors that will shed light on how best to offer and use planned OC. Topics include the pregnancy potential of oocytes retrieved at different ages with different markers for reproductive aging (antimullerian hormone, follicle-stimulating hormone, and antral follicle count); the health effects on those who are stimulated to produce oocytes when young; and the health effects for offspring, including long-term studies. Physicians who are providing planned OC should collect and share these data with patients and, to the extent possible, with the profession.

It also will be beneficial to continue to generate data on the social aspects of planned OC: the experiences and motivations of those who elect to cryopreserve oocytes, their experiences when attempting to use those oocytes, and the reflections of those who never use them. Recent research suggests that some individuals will experience decisional regret over having cryopreserved oocytes, a development that needs to be better understood and addressed (56, 58). Because lack of a partner is often offered as a reason for seeking planned OC, researchers should examine issues of male as well as female ‘‘procreative consciousness and decision-making’’ (59). In that regard, the availability of planned OC also creates opportunities for health professionals to fill the ‘‘knowledge gap’’ by educating the public about the limits of female fertility. In so doing, we may achieve an estimable goal: that fewer women will discover they are already in the phase of greatest fertility decline without ever having been taught of its existence.


The Committee concludes that planned OC may allow individuals who, in earlier times, would have faced infertility and childlessness to potentially have a child to whom they are genetically linked. Planned OC is an ethically permissible medical treatment that may enhance reproductive autonomy and promote social equality. As with any relatively new treatment, however, uncertainties exist regarding its efficacy and long-term effects. Patients considering this treatment must be apprised of these unknowns, whereas practitioners are strongly encouraged to gather and share data to add to scientific understanding about planned OC.


This report was developed under the direction of the Ethics Committee of the American Society for Reproductive Medicine as a service to its members and other practicing clinicians. Although this document reflects appropriate management of a problem encountered in the practice of reproductive medicine, it is not intended to be the only approved standard of practice or to dictate an exclusive course of treatment. Other plans of management may be appropriate, taking into account the needs of the individual patient, available resources, and institutional or clinical practice limitations. The Ethics Committee and the Board of Directors of the American Society for Reproductive Medicine have approved this report.

This document was reviewed by ASRM members, and their input was considered in the preparation of the final document. The following members of the ASRM Ethics Committee participated in the development of this document: Sigal Klipstein, M.D.; Deborah Anderson, Ph.D.; Kavita Shah Arora, M.D., M.B.E.; Tolulope Bakare, M.D.; Katherine Cameron, M.D.; Susan Crockin, J.D.; Ruth Farrell, M.D.; Jessica Goldstein, R.N.; Catherine Hammack-Aviran, M.A., J.D.; Marcelle Cedars, M.D.; Mandy Katz-Jaffe, Ph.D.; Jennifer Kawwass, M.D.; Edward Martinez, M.D.; Joshua Morris, M.D.; Jared Robins, M.D., M.B.A.; Gwendolyn Quinn, Ph.D.; Robert Rebar, M.D.; Jared Robins, M.D.; Chevis N Shannon, Dr.P.H., M.P.H., M.B.A.; Hugh Taylor, M.D.; Sean Tipton, M.A.; and Julianne Zweifel, Ph.D. The Ethics Committee acknowledges the special contribution of Ruth Farrell, M.D., and Mandy Katz-Jaffe, Ph.D., in the preparation of this document. All committee members disclosed commercial and financial relationships with manufacturers or distributors of goods or services used to treat patients. Members of the Committee who were found to have conflicts of interest based on the relationships disclosed did not participate in the discussion or development of this document.


  1. Practice Committees of the American Society for Reproductive Medicine and the Society for Assisted Reproductive Technology. Mature oocyte cryopreservation: a guideline. Fertil Steril 2013;99:37–43.
  2. Practice Committee of the American Society for Reproductive Medicine. Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion. Fertil Steril 2013;100:1214–23.
  3. Ethics Committee of the American Society for Reproductive Medicine. Fertility preservation and reproduction in patients facing gonadotoxic therapies: an Ethics Committee opinion. Fertil Steril 2018;110:380–6.
  4. Cobo A, García-Velasco JA, Coello A, Domingo J, Pellicer A, Remohí J. Oocyte vitrification as an efficient option for elective fertility preservation. Fertil Steril 2016;105:755–64.e8.
  5. Doyle JO, Richter KS, Lim J, Stillman RJ, Graham JR, Tucker MJ. Successful elective and medically indicated oocyte vitrification and warming for autologous in vitro fertilization, with predicted birth probabilities for fertility preservation according to number of cryopreserved oocytes and age at retrieval. Fertil Steril 2016;105:459–66.e2.
  6. Goldman KN, Labella PA, Grifo JA, McCulloh D, Noyes N. The evolution of oocyte cryopreservation (OC): longitudinal trends at a single center. Fertil Steril 2014;102:e164–5.
  7. Mucowski SJ, Bendikson K, Paulson R, Chung K. Current utilization status of cryopreserved oocytes in the United States. Fertil Steril 2014;101:e31–2.
  8. Argyle CE, Harper JC, Davies MC. Oocyte cryopreservation: where are we now? Hum Reprod Update 2016;22:440–9.
  9. The American Society for Reproductive Medicine Fact Sheet, ‘‘Can I freeze my eggs to use later if I'm not sick?’’ 2014. Available at: https://www. can-i-freeze-my-eggs-to-use-later-if-im-not-sick/. Accessed August 8, 2018.
  10. Ethics Committee of the American Society for Reproductive Medicine. Moving innovation to practice: an Ethics Committee opinion. Fertil Steril 2021; 116:331–6.
  11. Pennings G. Ethical aspects of social freezing. Gynecol Obstet Fertil 2013;41:521–3.
  12. Stoop D, van der Veen F, Deneyer M, Nekkebroeck J, Tournaye H. Oocyte banking for anticipated gamete exhaustion (AGE) is a preventive intervention, neither social nor nonmedical. Reprod Biomed Online 2014;28:548–51.
  13. Centers for Disease Control and Prevention. NCHS Data Brief: first births to older women continue to rise. Available at: products/databriefs/db152.htm. Accessed August 8, 2018.
  14. Cedars MI. Introduction: Childhood implications of parental aging. Fertil Steril 2015;103:1379–80.
  15. Schwartz D, Mayaux MJ. Female fecundity as a function of age: results of artificial insemination in 2193 nulliparous women with azoospermic husbands. Federation CECOS. N Engl J Med 1982;306:404–6.
  16. Mertes H. The portrayal of healthy women requesting oocyte preservation. Facts, vews, Vis ObGyn 2013;5:141–6.
  17. Barclay E. More women are freezing their eggs, but will they ever use them? NPR; November 25, 2015. Available from: 456671203/more-women-are-freezing-their-eggs-but-will-they-ever-use-them. Accessed August 8, 2018.
  18. Hodes-Wertz B, Druckenmiller S, Smith M, Noyes N. What do reproductive-age women who undergo oocyte cryopreservation think about the process as a means to preserve fertility? Fertil Steril 2013;100:1343–9.
  19. Barritt J, Luna M, Sandler B, Duke M, Copperman A. Elective oocyte freezing for the preservation of fertility. Open J Obstet Gynecol 2012;02:27–33.
  20. Lemoine ME, Ravitsky V. Sleepwalking into infertility: the need for a public health approach toward advanced maternal age. Am J Bioeth 2015;15:37–48.
  21. Petropanagos A. Reproductive ’choice’ and egg freezing. Cancer Treat Res 2010;156:223–35.
  22. Goldman KN, Grifo JA. Elective oocyte cryopreservation for deferred child-bearing. Curr Opin Endocrinol Diabetes Obes 2016;23:458–64.
  23. Devine K, Mumford SL, Goldman KN, Hodes-Wertz B, Druckenmiller S, Propst AM, et al. Baby budgeting: oocyte cryopreservation in women delaying reproduction can reduce cost per live birth. Fertil Steril 2015;103: 1446–53.e1.
  24. Cobo A, García-Velasco JA. Why all women should freeze their eggs. Curr Opin Obstet Gynecol 2016;28:206–10.
  25. Cascante SD, Blakemore JK, DeVore S, Hodes-Wertz B, fino ME, Berkeley AS, et al. fifteen years of autologous oocyte thaw outcomes from a large university-based fertility center. Fertil Steril 2022;118:158–66.
  26. Maslow BL, Guarnaccia MM, Ramirez L, Klein JU. Likelihood of achieving a 50%, 60%, or 70% estimated live birth rate threshold with 1 or 2 cycles of planned oocyte cryopreservation. J Assist Reprod Genet 2020;37:1637–43.
  27. Blakemore JK, Grifo JA, DeVore SM, Hodes-Wertz B, Berkeley AS. Planned oocyte cryopreservation-10-15-year follow-up: return rates and cycle outcomes. Fertil Steril 2021;115:1511–20.
  28. Leung AQ, Baker K, Vaughan D, Shah JS, Korkidakis A, Ryley DA, et al. Clinical outcomes and utilization from over a decade of planned oocyte cryopreservation. Reprod Biomed Online 2021;43:671–9.
  29. Petropanagos A, Cattapan A, Baylis F, Leader A. Social egg freezing: risk, benefits and other considerations. CMAJ 2015;187:666–9.
  30. Rabinowitz A. Why egg freezing is an impossible choice. Nautilus. Available at: Accessed August 8, 2018.
  31. Kawwass JF, Crawford S, Hipp HS. Frozen eggs: national autologous oocyte thaw outcomes. Fertil Steril 2021;116:1077–84.
  32. Practice Committee of the American Society for Reproductive Medicine. Evidence-based outcomes after oocyte cryopreservation for donor oocyte in vitro fertilization and planned oocyte cryopreservation: a guideline. Fertil Steril 2021;116:36–47.
  33. Bernstein S, Wiesemann C. Should postponing motherhood via ’’social freezing’’ be legally banned? An ethical analysis. Laws 2014;3:282–300.
  34. Gold E, Copperman K, Witkin G, Jones C, Copperman AB. A motivational assessment of women undergoing elective egg freezing for fertility preservation. Fertil Steril 2006;86:S201.
  35. Johnston J, Zoll M. Is freezing your eggs dangerous? A primer. New Republic. Available at: Accessed August 8, 2018.
  36. Practice Committee of the American Society for Reproductive Medicine. Prevention and treatment of moderate and severe ovarian hyperstimulation syndrome: a guideline. Fertil Steril 2016;106:1634–47.
  37. Levi-Setti PE, Borini A, Patrizio P, Bolli S, Vigiliano V, De Luca R, et al. ART results with frozen oocytes: data from the Italian ART registry (2005-2013). J Assist Reprod Genet 2016;33:123–8.
  38. Da Luz CM, Caetano MA, Berteli TS, Vireque AA, Navarro PA. The impact of oocyte vitrification on offspring: a systematic review. Reprod Sci 2022;29: 3222–34.
  39. Schattman GL. CLINICAL PRACTICE. Cryopreservation of oocytes. N Engl J Med 2015;373:1755–60.
  40. Spar D. Should you freeze your eggs? Marie Claire. Available at: http://www. Accessed August 8, 2018.
  41. Robertson JA. Egg freezing and egg banking: empowerment and alienation in assisted reproduction. J Law Biosci 2014;1:113–36.
  42. ESHRE Task Force on Ethics and Law, Dondorp W, de Wert G, Pennings G, Shenfield F, Devroey P, et al. Oocyte cryopreservation for age-related fertility loss. Hum Reprod 2012;27:1231–7.
  43. Potdar N, Gelbaya TA, Nardo LG. Oocyte vitrification in the 21st century and post-warming fertility outcomes: a systemic review and meta-analysis. Reprod Biomed Online 2014;29:159–76.
  44. Mesen TB, Mersereau JE, Kane JB, Steiner AZ. Optimal timing for elective egg freezing. Fertil Steril 2015;103(6):1551–6.e1– 4.
  45. Furedi A. Trust women to decide the right time to have a family. BioNews 2015. Available at: Accessed August 8, 2018.
  46. Goldman RH, Racowsky C, Farland LV, Munn'e S, Ribustello L, Fox JH. Predicting the likelihood of live birth for elective oocyte cryopreservation: a counseling tool for physicians and patients. Hum Reprod 2017;32: 853–9.
  47. Allen R. Is egg freezing only for white women? NYT; May 22, 2016. Available at: Accessed August 9, 2016.
  48. Katler QS, Shandley LM, Hipp HS, Kawwass JF. National egg-freezing trends: cycle and patient characteristics with a focus on race/ethnicity. Fertil Steril 2021;116:528–37.
  49. Mertes H. Does company-sponsored egg freezing promote or confine women’s reproductive autonomy? J Assist Reprod Genet 2015;32:1205–9.
  50. Baldwin K, Culley L, Hudson N, Mitchell H. Reproductive technology and the life course: current debates and research in social egg freezing. Hum Fertil (Camb) 2014;17:170–9.
  51. Sauer MV. Reproduction at an advanced maternal age and maternal health. Fertil Steril 2015;103:1136–43.
  52. Ethics Committee of the American Society for Reproductive Medicine. Oocyte or embryo donation to women of advanced maternal age: an Ethics Committee opinion. Fertil Steril 2016;106:e3–7.
  53. Kime P. Military’s new fertility benefit will let troops freeze their sperm and eggs; January 29, 2016. Military Times. Available at: https://www. military-s-new-fertility-benefit-will-let-troops-freeze-their-sperm-and-eggs/. Accessed August 8, 2018.
  54. Hotakainen R. GOP objection kills Senate funding for military fertility program. McClatchy DC bureau. June 14, 2016. Available at:  html. Accessed March 26, 2017.
  55. Harwood K. Egg freezing: a breakthrough for reproductive autonomy? Bioethics 2009;23:39–46.
  56. Greenwood EA, Pasch LA, Hastie J, Cedars MI, Huddleston HG. To freeze or not to freeze: decision regret and satisfaction following elective oocyte cryopreservation. Fertil Steril 2018;109:1097–104.e1.
  57. Ethics Committee of American Society for Reproductive Medicine. Informed consent and the use of gametes and embryos for research: a committee opinion. Fertil Steril 2014;101:332–5.
  58. Goldman KN. Elective oocyte cryopreservation: an ounce of prevention? Fertil Steril 2018;109:1014–5.
  59. Marsiglio W, Lohan M, Culley L. Framing men’s experience in the procreative realm. J Fam Issues 2013;3:1011–36.

Ethics Opinions

Ethics Committee Reports are drafted by the members of the ASRM Ethics Committee on the tough ethical dilemmas of reproductive medicine.
Ethics Committee teaser

Family members as gamete donors or gestational carriers: an Ethics Committee opinion (2024)

The use of adult intrafamilial gamete donors and gestational surrogates is ethically acceptable when all participants are fully informed and counseled.
Ethics Committee teaser

Financial ‘‘risk-sharing’’ or refund programs in assisted reproduction: an Ethics Committee opinion (2023)

Financial ‘‘risk-sharing’’ fee structures in programs charge patients a higher initial fee but provide reduced fees for subsequent cycles.
Ethics Committee teaser

Planned oocyte cryopreservation to preserve future reproductive potential: an Ethics Committee opinion (2023)

Planned oocyte cryopreservation is an ethically permissible procedure that may help individuals avoid future infertility.
Ethics Committee teaser

Ethical obligations in fertility treatment when intimate partners withhold information from each other: an Ethics Committee opinion (2024)

Clinicians should encourage disclosure between intimate partners but should maintain confidentiality where there is no harm to the partner and/or offspring.

More Resources

MAC 2021 teaser
ASRM Academy on the Go

ASRM MAC Tool 2021

The ASRM Müllerian Anomaly Classification 2021 (MAC2021) includes cervical and vaginal anomalies and standardize terminology within an interactive tool format.

View the MAC Tool
EMR Phrases teaser
Practice Guidance

EMR Shared Phrases/Template Library

This resource includes phrases shared by ASRM physician members to provide a template for individuals to create their own EMR phrases.

View the library
Practice Committee Documents teaser

ASRM Practice Documents

These guidelines have been developed by the ASRM Practice Committee to assist physicians with clinical decisions regarding the care of their patients.

View ASRM Practice Documents
Ethics Committee teaser

ASRM Ethics Opinions

Ethics Committee Reports are drafted by the members of the ASRM Ethics Committee on the tough ethical dilemmas of reproductive medicine.

View ASRM Ethics Opinions
Coding Corner general teaser
Practice Guidance

Coding Corner Q & A

The Coding Corner Q & A is a list of previously submitted and answered questions from ASRM members about coding. Answers are available to ASRM Members only.

View the Q & A
Covid-19 teaser
Practice Guidance

COVID-19 Resources

A compendium of ASRM resources concerning the Novel Corona virus (SARS-COV-2) and COVID-19.

View the resources
Couple looking at laptop for online patient education materials

Patient Resources provides a wide range of information related to reproductive health and infertility through patient education fact sheets, infographics, videos, and other resources.

View Website

Topic Resources

View more on the topic of cryopreservation
Coding Icon

TESE test thaws

We perform test thaws to determine if frozen TESE specimens from other clinics are suitable for our procedures. View the Answer
Document Icon

Planned oocyte cryopreservation to preserve future reproductive potential: an Ethics Committee opinion (2023)

Planned oocyte cryopreservation is an ethically permissible procedure that may help individuals avoid future infertility. View the Committee Opinion
Coding Icon

Coding for ovarian tissue cryopreservation

For Cryopreservation; Reproductive Tissue Ovarian- 0058T code is not being recognized. Is there an updated one being used or a replacement of this code? View the Answer
Coding Icon

Billing for cryopreservation procedures on different days

I understand that if cryopreservation of oocytes is performed on two separate dates of service, each date of service was billable. View the Answer
Coding Icon

Reimbursement for cost of donor egg

My wife and I are going through a fertility treatment process, and we have purchased a donor egg out-of-pocket from a donor bank.  View the Answer
Coding Icon

Coding for Ovarian tissue cryopreservation, experimental or not?

For Cryopreservation; Reproductive Tissue Ovarian- 0058T code is not being recognized. Is there an updated one being used or a replacement of this code? View the Answer
Coding Icon

Does the number of eggs being frozen matter?

There is currently only one CPT code for the cryopreservation of mature oocytes and embryos.  View the Answer
Coding Icon

Semen Freezing

We have a couple who are doing an IUI cycle. View the Answer
Coding Icon

Sperm Prep in Office vs. Lab

What are the codes for sperm washing when performed in the office vs in a CLIA certified lab? View the Answer
Coding Icon

Sperm Preparation IUI and IVF

What semen analysis codes apply to sperm preparation for IUI or IVF? View the Answer
Coding Icon

Reproductive Tissue Storage

What are the CPT codes for the Storage of Reproductive Cells/Tissues? View the Answer
Coding Icon

Office Testicular Aspiration

We are inquiring about a coding question for testicular aspirations.  View the Answer
Coding Icon

IVF Case Rates

What ICD-10 codes apply to case rates? View the Answer
Coding Icon

Oocyte Preservation Consult

Our center performs oocyte preservation procedures for women looking to preserve their fertility. View the Answer
Coding Icon

In Vitro Maturation

Have CPT codes been established for maturation in vitro? View the Answer
Coding Icon

Embryo Storage Fees For Multiple Cycles

We bill embryo storage 89342 for a year's storage.  View the Answer
Coding Icon

Frozen Embryo Transport

What is the code for the cost of frozen embryo transport? View the Answer
Coding Icon

Gamete Thawing/Warming

Can patients be charged for each vial/straw of reproductive gametes or tissues thawed? View the Answer
Coding Icon

Billing For Cryopreservation Of Embryos Under The Male Partner

Can 89258 be billed under the male partner of a female patient? View the Answer
Coding Icon

Coding For Long-Term Storage Of Embryos

We have recently been contacted by a payer stating we have a patient whose plan will cover long-term storage of her embryos. View the Answer
Coding Icon

Coding For Ovarian Tissue Cryopreservation

Now that ASRM has removed the "experimental" designation from ovarian tissue cryopreservation what CPT code should be used instead of 0058T? View the Answer
Coding Icon

Cryopreservation/Vitrification Oocytes/Embryos

What are the correct codes for cryopreservation/Vitrification Oocytes/Embryos? View the Answer
Coding Icon

Cryopreservation/Vitrification Sperm/Testicular Tissues

What are the correct codes for the Cryopreservation/Vitrification of Sperm or testicular tissues? View the Answer
Videos Icon

Journal Club Global: Should everyone freeze oocytes by age 33?

Oocyte cryopreservation is one of the fastest growing areas of reproductive medicine. View the Video
Document Icon

Ethical issues in oocyte banking for nonautologous use: an Ethics Committee opinion (2021)

Medical guidelines applicable to women donating fresh oocytes should also apply to women donating oocytes to an oocyte bank. View the Committee Opinion
Document Icon

Evidence-based outcomes after oocyte cryopreservation for donor oocyte in vitro fertilization and planned oocyte cryopreservation: a guideline (2021)

A review of success rates, factors that may impact success rates, and  outcomes. View the Committee Opinion
Document Icon

Development of an emergency plan for in vitro fertilization programs: a committee opinion (2021)

All IVF programs and clinics should have a plan to protect fresh and cryopreserved human specimens (embryos, oocytes, sperm). View the Committee Opinion
Document Icon

Cryostorage of reproductive tissues in the in vitro fertilization laboratory: a committee opinion (2020)

This document is designed to assist IVF clinics in the management of cryopreserved reproductive tissues stored in cryogenic storage. View the Committee Opinion
Document Icon

Fertility preservation and reproduction in patients facing gonadotoxic therapies: an Ethics Committee opinion (2018)

Chemotherapy and radiation therapy often result in reduced fertility. View the Committee Opinion
Document Icon

Best practices of ASRM and ESHRE: a journey through reproductive medicine (2012)

ASRM and ESHRE are the two largest societies in the world whose members comprise the major experts and professionals working in reproductive medicine. View the Committee Joint Guideline

Topic Resources

View more on the topic of fertility preservation
Coding Icon

Reimplantation of cryopreserved ovarian tissue

What is the correct code for laparoscopic reimplantation of ovarian tissue?  View the Answer
Document Icon

Planned oocyte cryopreservation to preserve future reproductive potential: an Ethics Committee opinion (2023)

Planned oocyte cryopreservation is an ethically permissible procedure that may help individuals avoid future infertility. View the Committee Opinion
Coding Icon

Z Codes Vs. Procedure Codes For Fertility Preservation Counseling

I am trying to understand better when to use the procreative management code vs the fertility preservation counseling and procedure codes. View the Answer
Coding Icon

Elective fertility preservation is ART

From an insurance standpoint, is fertility preservation is considered an assisted reproductive technology or would it be branched under other?  View the Answer
Coding Icon

Oocyte Preservation Consult

Our center performs oocyte preservation procedures for women looking to preserve their fertility. View the Answer
Coding Icon

Fertility Preservation Consult

What code are we supposed to use for counseling regarding fertility preservation for an individual with cancer... View the Answer
Coding Icon

Cycle Monitoring Fertility Preservation

If the patient is undergoing ultrasound tracking visits for fertility preservation, what I ICD-10 code do you use for the monitoring? View the Answer
Coding Icon

Coding For Ovarian Tissue Cryopreservation

Now that ASRM has removed the "experimental" designation from ovarian tissue cryopreservation what CPT code should be used instead of 0058T? View the Answer
Coding Icon

Fertility Preservation

A summary of codes for Fertility Preservation compiled by the ASRM Coding Committee. View the Coding Summary
Document Icon

Reproductive and hormonal considerations in women at increased risk for hereditary gynecologic cancers: Society of Gynecologic Oncology and American Society for Reproductive Medicine Evidence-Based Review (2019)

Providers who care for women at risk for hereditary gynecologic cancers must consider the impact of these conditions. View the Joint Statement
Document Icon

Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion (2019)

Patients preparing to undergo gonadotoxic medical therapy, radiation therapy, or gonadectomy should be provided with prompt counseling regarding available options for fertility preservation for iatrogenic infertility. View the Committee Opinion
Document Icon

Fertility preservation and reproduction in patients facing gonadotoxic therapies: an Ethics Committee opinion (2018)

Chemotherapy and radiation therapy often result in reduced fertility. View the Committee Opinion
Membership Icon

Fertility Preservation Special Interest Group (FPSIG)

The FPSIG promotes knowledge on infertility induced by cancer therapy and other medical treatments. Learn more about FPSIG